These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 21843259

  • 21. Enhancement of nab-paclitaxel antitumor activity through addition of multitargeting antiangiogenic agents in experimental pancreatic cancer.
    Awasthi N, Zhang C, Schwarz AM, Hinz S, Schwarz MA, Schwarz RE.
    Mol Cancer Ther; 2014 May; 13(5):1032-43. PubMed ID: 24608575
    [Abstract] [Full Text] [Related]

  • 22. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M.
    Br J Cancer; 2016 Aug 09; 115(4):442-53. PubMed ID: 27441498
    [Abstract] [Full Text] [Related]

  • 23. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
    Karaca M, Dutta R, Ozsoy Y, Mahato RI.
    Mol Pharm; 2016 Jun 06; 13(6):1822-32. PubMed ID: 26981724
    [Abstract] [Full Text] [Related]

  • 24. Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
    Awasthi N, Hinz S, Brekken RA, Schwarz MA, Schwarz RE.
    Cancer Lett; 2015 Mar 01; 358(1):59-66. PubMed ID: 25527450
    [Abstract] [Full Text] [Related]

  • 25. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
    Awasthi N, Schwarz MA, Schwarz RE.
    Cancer Biol Ther; 2010 Jul 01; 10(1):99-107. PubMed ID: 20495354
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.
    Cancer Lett; 2017 Aug 28; 402():1-8. PubMed ID: 28536008
    [Abstract] [Full Text] [Related]

  • 28. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K, Aiura K, Matsuda S, Itano O, Takeuchi O, Umezawa K, Kitagawa Y.
    Clin Exp Metastasis; 2013 Apr 28; 30(4):381-92. PubMed ID: 23111540
    [Abstract] [Full Text] [Related]

  • 29. Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
    Johnson JL, Dia VP, Wallig M, Gonzalez de Mejia E.
    Pancreas; 2015 Jan 28; 44(1):144-51. PubMed ID: 25237909
    [Abstract] [Full Text] [Related]

  • 30. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
    Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.
    Eur J Pharmacol; 2004 Sep 13; 498(1-3):9-18. PubMed ID: 15363970
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T, Ren H, Jia L, Chen J, Xin W, Yan F, Li J, Wang X, Gao S, Qian D, Huang C, Hao J.
    Oncotarget; 2015 Feb 10; 6(4):2250-62. PubMed ID: 25544770
    [Abstract] [Full Text] [Related]

  • 39. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Pan CH, Otsuka Y, Sridharan B, Woo M, Leiton CV, Babu S, Torrente Gonçalves M, Kawalerski RR, K Bai JD, Chang DK, Biankin AV, Scampavia L, Spicer T, Escobar-Hoyos LF, Shroyer KR.
    Mol Oncol; 2020 Aug 10; 14(8):1800-1816. PubMed ID: 32533886
    [Abstract] [Full Text] [Related]

  • 40. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S, Buchy E, Askin G, Cayre F, Mougin J, Gouazou S, Sobot D, Valetti S, Stella B, Desmaele D, Couvreur P.
    Biochimie; 2016 Nov 10; 130():4-13. PubMed ID: 27519301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.